Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update

Abstract

Precision oncology is now the evidence-based standard of care for the management of many advanced non-small cell lung cancers (NSCLC). Notably, new molecular profiling technologies have permitted dynamic growth in the identification of actionable driver oncogenes including RET rearrangements. RET oncogenes cannot be adequately detected by immunohistochemistry, although fluorescence in situ hybridization, reverse transcriptase polymerase chain reaction and next-generation sequencing are complementary diagnostic tools. In the clinical setting, the benefit of the most developed RET inhibitors, i.e., cabozantinb, vandetanib and lenvatinb, in terms of response and median progressionfree survival has been demonstrated. The absence of striking clinical results of RET inhibitors underscores the clear need for development of more selective and potent RET inhibitors. This paper reviews the clinical data available on RET inhibitors in RET-associated NSCLC.

Downloads

Download data is not yet available.
Published
2018-07-10
Section
Reviews
Keywords:
Non-small cell lung cancer, RET-rearrangement, clinical trials, review, tyrosine kinase.
Statistics
Abstract views: 578

PDF: 389
HTML: 18
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Mendoza, L. (2018). Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update. Oncology Reviews, 12(2). https://doi.org/10.4081/oncol.2018.352